Arca
Skip to content
Tools
Tools

TNFSF13: Tumor necrosis factor ligand superfamily member 13

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on TNFSF13, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Protein or peptide

Approved0

    Phase 31

    • Atacicept

    Phase 21

    • Sibeprenlimab

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      AtaciceptPhase 3Vera TherapeuticsProtein or peptideInhibitorTumor necrosis factor ligand superfamily member 13 inhibitor4—
      SibeprenlimabPhase 2Otsuka PharmaceuticalAntibodyInhibitorTumor necrosis factor ligand superfamily member 13 inhibitor7—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
      A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeSibeprenlimabPhase 3RecruitingVertex Pharmaceuticals Incorporated2026-10-22
      A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseSibeprenlimabPhase 2Not yet recruitingOtsuka Pharmaceutical Development & Commercialization, Inc.2026-10-06
      Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)SibeprenlimabPhase 3Not yet recruitingOtsuka Pharmaceutical Development & Commercialization, Inc.2026-08-18
      Monthly Dosing of Atacicept in IgANAtaciceptPhase 2Active, not recruitingVera Therapeutics, Inc.2025-06-13
      Atacicept in Multiple Glomerular DiseasesAtaciceptPhase 2RecruitingVera Therapeutics, Inc.2025-05-21
      A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sSibeprenlimabPhase 2Active, not recruitingOtsuka Pharmaceutical Development & Commercialization, Inc.2025-04-15
      Phase 2b Open-Label Repeat Kidney Biopsy StudySibeprenlimabPhase 2Active, not recruitingOtsuka Pharmaceutical Development & Commercialization, Inc.2024-12-18
      A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptAtaciceptPhase 2Enrolling by invitationVera Therapeutics, Inc.2024-11-05
      Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)SibeprenlimabPhase 3Active, not recruitingOtsuka Pharmaceutical Development & Commercialization, Inc.2022-02-21
      Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)SibeprenlimabPhase 2 / Phase 3Enrolling by invitationOtsuka Pharmaceutical Development & Commercialization, Inc.2022-02-21
      Atacicept in Subjects With IgA NephropathyAtaciceptPhase 3Active, not recruitingVera Therapeutics, Inc.2021-01-20

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Snoring
      0.41
      Hypertensive disorder
      0.29
      Abnormality of the skeletal system
      0.26
      Familial hyperlipidemia
      0.21

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713436, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt O75888, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.